Retifanlimab
Cutaneous Neuroendocrine Carcinoma
Explore 45 assets in Cutaneous Neuroendocrine Carcinoma →Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Ariceum Therapeutics GmbH
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06939036CT.gov Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Retifanlimab (this asset) | Ariceum Therapeutics GmbH | P1/2 | CC · 45 |
| Pembrolizumab | Merck Sharp & Dohme LLC | P3 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P2/3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P2 | B |
| Durvalumab | Ariceum Therapeutics GmbH | P2 | B |
| Atezolizumab | Ariceum Therapeutics GmbH | P2 | B |
| Ifx-Hu2.0 | TuHURA Biosciences, Inc. | P2/3 | B |
| Fludarabine | Sotio Biotech Inc. | P2 | B |
| ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE | University of Zurich | P2 | B |
+42 more in the Cutaneous Neuroendocrine Carcinoma cohort
Other indications for Retifanlimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Anal Canal Squamous Cell Carcinoma | — | P3 | BB · 66 |
| Urothelial Carcinoma | — | P2 | BB · 66 |
| Renal Cell Carcinoma | — | P2 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Retifanlimab in Cutaneous Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/retifanlimab-cutaneous-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →